Clinical Trials Logo

Stage IVA Ovarian Cancer AJCC v8 clinical trials

View clinical trials related to Stage IVA Ovarian Cancer AJCC v8.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04501913 Active, not recruiting - Malignant Neoplasm Clinical Trials

Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes

Start date: December 24, 2019
Phase:
Study type: Observational

This study examines at-home monitoring of patient-generated phsyiologic health data and patient-reported outcomes. Patient-generated health data using at-home monitoring devices and smart device applications are used more and more to measure value and quality in cancer care. This trial may show whether at-home monitoring programs can improve the care of patients after hospital discharge from surgery.

NCT ID: NCT03943173 Active, not recruiting - Clinical trials for Stage IV Ovarian Cancer AJCC v8

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

Start date: June 7, 2019
Phase: Early Phase 1
Study type: Interventional

This early phase I trial studies how well olaparib works in treating patients with newly diagnosed BRCA-mutant ovarian, primary peritoneal, or fallopian cancer before surgery. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03707574 Active, not recruiting - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

Start date: April 9, 2019
Phase:
Study type: Observational

This trial studies the genetic analysis of blood and tissue samples from patients with cancer that has spread to other anatomic sites (advanced) or is no longer responding to treatment. Studying these samples in the laboratory may help doctors to learn how genes affect cancer and how they affect a person's response to treatment.

NCT ID: NCT03508570 Active, not recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

Start date: September 21, 2018
Phase: Phase 1
Study type: Interventional

This phase Ib trial studies the side effects and best dose of nivolumab with or without ipilimumab in treating patients with female reproductive cancer that has come back (recurrent) or is high grade and has spread extensively throughout the peritoneal cavity (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT02650986 Active, not recruiting - Metastatic Melanoma Clinical Trials

Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Start date: July 14, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/IIa trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens 1 (NY-ESO-1) gene that have spread to other places in the body (advanced). A T cell is a type of immune cell that can recognize and kill abnormal cells of the body. Placing a modified gene for NY-ESO-1 into the patients' T cells in the laboratory and then giving them back to the patient may help the body build an immune response to kill tumor cells that express NY-ESO-1. Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving gene-modified T cells with or without decitabine works better in treating patients with malignancies expressing NY-ESO-1.